Literature DB >> 18979362

A palmitoylated peptide, derived from the acidic carboxyl-terminal segment of the integrin alphaIIb cytoplasmic domain, inhibits platelet activation.

Vassiliki Koloka1, Elena D Christofidou, Spyros Vaxevanelis, Andromaxi A Dimitriou, Vassilios Tsikaris, Alexandros D Tselepis, Eugenia Panou-Pomonis, Maria Sakarellos-Daitsiotis, Demokritos C Tsoukatos.   

Abstract

Platelet integrin alpha(IIb)beta(3) contains an acidic membrane distal motif, 1000LEEDDEEGE1008, in the cytoplasmic domain of the alpha(IIb) subunit. We showed that a lipid-modified peptide corresponding to the above region, palmitoyl-K-LEEDDEEGE (pal-K-1000-1008), is platelet permeable and has inhibited platelet aggregation induced by 0.4 U/ml of thrombin (IC50 = 164 microM). Moreover the peptide inhibited both Fibrinogen and PAC-1, binding to activated platelets. The non palmitoylated analog was inactive. A modified, scrambled acidic peptide (palmitoyl-K-GDDEELEEE), showed significant lower inhibitory activity than pal-K-1000-1008. A palmitoylated peptide corresponding to the membrane proximal cytoplasmic domain of alpha(IIb), 989KGVFFKR995 (pal-989-995), is known to specifically induce platelet aggregation. Pal-K-1000-1008 was an inhibitor of human washed platelet aggregation induced by pal-K-989-995 (IC50 = 15 microM). Moreover, pal-K-1000-1008 inhibited phosphorylation of ERK and FAK, two protein kinases involved in platelet activation and aggregation. Our results favour the assumption that the interaction of the membrane proximal sequence 989KGVFFKR995 of the cytoplasmic domain of alpha(IIb) with the acidic terminal 1000LEEDDEEGE1008 motif may be an important structural factor in platelet signaling, leading to platelet activation and aggregation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18979362     DOI: 10.1080/09537100802266875

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  6 in total

Review 1.  Targeting integrin and integrin signaling in treating thrombosis.

Authors:  Brian Estevez; Bo Shen; Xiaoping Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

Review 2.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

3.  Structural basis for the activation of platelet integrin αIIbβ3 by calcium- and integrin-binding protein 1.

Authors:  Hao Huang; Hans J Vogel
Journal:  J Am Chem Soc       Date:  2012-02-16       Impact factor: 15.419

4.  The membrane-distal regions of integrin α cytoplasmic domains contribute differently to integrin inside-out activation.

Authors:  Aye Myat Myat Thinn; Zhengli Wang; Jieqing Zhu
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

5.  Peptides derived from cadherin juxtamembrane region inhibit platelet function.

Authors:  Kalyan Golla; Ilias Stavropoulos; Denis C Shields; Niamh Moran
Journal:  R Soc Open Sci       Date:  2018-10-10       Impact factor: 2.963

6.  Computational and experimental analysis of bioactive peptide linear motifs in the integrin adhesome.

Authors:  Kevin T O'Brien; Kalyan Golla; Tilen Kranjc; Darragh O'Donovan; Seamus Allen; Patricia Maguire; Jeremy C Simpson; David O'Connell; Niamh Moran; Denis C Shields
Journal:  PLoS One       Date:  2019-01-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.